Hormonal
GLP-1 RAs promote significant weight loss (up to 18-21% in clinical trials) by acting on central brain regions to modify food preferences, reduce appetite, and increase satiety.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, achieving 18-21% body weight reduction in clinical trials. They work by changing how your brain signals hunger and fullness, not just by making you feel full. This can be particularly helpful if you have struggled with dieting in the past. Combining the medication with behavioral therapy yields the best results.
Current knowledge links weight loss with GLP- 1 RAs to central effects in brain regions expressing the GLP- 1R, modifying food preferences, reducing appetite and food intake, and increasing satiety. ... semaglutide, was approved with weight loss of up to around 18% after 68 weeks shown in phase 3 development... tirzepatide... appears promising in obesity management with weight loss of up to around 21% after 72 weeks in phase 3
Why this rating
Based on Phase 3 clinical trials (STEP program, SURPASS) with large sample sizes.
Source
Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials
Frederik Flindt Kreiner et al. · Aging Cell · 2023
DOI 10.1111/acel.13818
More from this paper
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular events (MACE) by approximately 14% in patients with type 2 diabetes, independent of glucose-lowering effects.Strong
- GLP-1 RAs show potential to slow the progression of neurodegenerative diseases, including Alzheimer's and Parkinson's, by reducing neuroinflammation and potentially acting as neuroprotective agents.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →